SIMPONI® (golimumab) shows higher treatment persistence rates in patients with immune-mediated rheumatic diseases
Συγγραφέας iator Γράφτηκε στις ,
Higher persistence in these patients may be associated with lower healthcare costs
MSD, (Merck & Co., Inc., Kenilworth, NJ, USA in the United States and Canada), announced the publication of the results of a retrospective analysis of a large Swedish prescription registry study, which described real-world treatment persistence in patients with immune-mediated rheumatic disease (IMRD) newly treated with different subcutaneous tumor necrosis factor-alpha inhibitors (SC-TNFi).1
A total of 4,903 patients with ankylosing spondylitis, psoriatic arthritis or rheumatoid arthritis (collectively referred to as IMRD) were included in the study.
The study results show that SC-TNFi-naïve IMRD patients initiating treatment with golimumab in Sweden had significantly higher persistence rates than patients initiating treatment with adalimumab or etanercept.
In these analyses, Kaplan-Meier survival estimates at 3 years were golimumab 40% versus adalimumab 33%, and golimumab 39% versus etanercept 29%
The study also indicated that treatment persistence with SC-TNFi may be associated with lower health care resource utilisation (HCRU) costs comprising specialised outpatient care, inpatient care and non-disease-modifying antirheumatic drug (DMARD) medications.
“This real-world study demonstrated that, in SC-TNFi-naïve IMRD patients, Simponi had significantly higher persistence rates compared with Humira and Enbrel. These results support existing long-term Simponi data for persistence,” comments Sumesh Kachroo, Director of Outcomes Research at MSD and Swedish registry publication author.
As persistence rates observed across all treatments in this study were lower than those observed in clinical trials, the study authors suggest the need for all-party (provider-patient-payer-drug manufacturer) engagement and development of programmes to increase persistence rates in clinical practice, to improve clinical outcomes.
Effects of non-persistence on healthcare resource utilisation (HCRU) costs
A secondary objective of the study was to describe potential effects on HCRU cost from non-persistence.
The analysis of costs was carried out on a subset of patients with at least 24 months of follow-up and stratified by persistence status at 12 months post-treatment initiation.
Patients who were persistent at 12 months incurred lower non-DMARD HCRU costs than patients who were not persistent over the same period, with an average of 1,574 Euros higher costs for non-persistent patients when taking differences in costs prior to treatment initiation into account.
“This is thought to be the first study in a European setting that shows that persistence in treatment with SC-TNFi may be associated with cost offsets,” explains Sumesh Kachroo. “This provides further evidence for the need of an all-inclusive approach involving provider-patient-payer-drug manufacturer to find ways to increase persistence rates in real-world settings”.
